Company description

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. These enable our customers to commercialize their discoveries and innovations in the healthcare sector.

Lonza’s industry-leading Capsugel® capsules and encapsulation technologies, formulation know-how and science-backed ingredients combined with our customer-focused services, provide unique and innovative solutions for nutraceutical companies.

Founded in 1897 in the Swiss Alps, today Lonza operates across three continents. With approximately 14,000 full-time employees, we are built from high-performing teams and of individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 4.5 billion in 2020 with a CORE EBITDA of CHF 1.4 billion.  Find out more on www.lonza.com

Quick facts

Affiliated categories: Collagen |Contract manufacturing |Encapsulation More

Upcoming events

22 nov 2021

Fi Europe Online and In-Person

22 November - 2 December 2021 Frankfurt, Germany Visit us at stand 30G40 Book a meeting See our Exhibitor Profile   See full Exhibitor List

Recently at

14 jun 2021

Fi Global CONNECT - Health Ingredients in the Spotlight

14 - 18 June 2021 We were at stand 6 See our Exhibitor Profile   See full Exhibitor List
12 apr 2021

Fi Global CONNECT – Regions in the Spotlight

12 - 23 April 2021 We were at stand 27 See our Exhibitor Profile   See full Exhibitor List
23 nov 2020

Fi Europe Connect 2020

23 November - 4 December We were at stand 47, 48 See our Exhibitor Profile   See full Exhibitor List

News about Capsugel Belgium NV

Moving With the Times: Next Generation Joint Health Innovation

20 Nov 2020

Moving With the Times: Next Generation Joint Health Innovation

With today’s aging population, mobility means much more than just getting from A to B. Maintaining the ability to move around like we always have becomes a top priority for many people as we get older, impacting on overall health and wellbeing as well as quality of life for both individuals and their families.

Read more

4 Sep 2019

BacThera gets regulatory approval

Chr. Hansen and Lonza have received the relevant approvals from anti-trust regulators needed to establish the 50/50 joint venture in the emerging market for live biotherapeutic products, which was originally announced on April 2, 2019.

Read more

4 Feb 2019

Lonza reports 9% organic sales growth

Having completed the first full year with Capsugel as a combined company, Lonza has reported a 9% organic (like-for-like) sales, 12% organic core EBITDA and 14% organic core EBIT growth.

Read more

Categories affiliated with Capsugel Belgium NV